Clin Mol Hepatol.  2015 Jun;21(2):115-121. 10.3350/cmh.2015.21.2.115.

New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis

• Woo HY
• Heo J

• KMID: 2164360
• DOI: http://doi.org/10.3350/cmh.2015.21.2.115

Abstract

Despite advances in the treatment of hepatocellular carcinoma (HCC), managing HCC with portal vein thrombosis (PVT) remains challenging. PVT is present in 10-40% of HCC cases at the time of diagnosis and its therapeutic options are very limited. Current guidelines mainly recommend sorafenib for advanced HCC with PVT, but surgery, transarterial chemoemolization, external radiation therapy, radioembolization, transarterial infusion chemotherapy, and combination therapy are also still used. Furthermore, several new emerging therapies such as the administration of immunotherapeutic agents and oncolytic viruses are under investigation. This comprehensive literature review presents current and future management options with their relative advantages and disadvantages and summary data on overall survival.

Keyword

Management; Hepatocellular carcinoma; Portal vein thrombosis

MeSH Terms

Carcinoma, Hepatocellular/complications/*pathology/therapy
Chemoembolization, Therapeutic
Combined Modality Therapy
Humans
Liver Neoplasms/complications/*pathology/therapy
Niacinamide/administration & dosage/analogs & derivatives
Phenylurea Compounds/administration & dosage
Portal Vein
Protein Kinase Inhibitors/administration & dosage
Venous Thrombosis/complications/*pathology
Niacinamide
Phenylurea Compounds
Protein Kinase Inhibitors